-
Mashup Score: 0Unlocking Cancer Treatment: Nivolumab & Ipilimumab Explored - 8 month(s) ago
In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with INT230-6 alone led to extended survival among patients with soft tissue sarcoma by nearly 450 days, compared with synthetic controls, and demonstrated a favorable safety profile.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab Combinations Improve Survival But Are Not Cost-Prohibitive in Advanced ESCC - 11 month(s) ago
An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patients With Poor-Prognosis Metastatic NSCLC Benefit From Nivolumab and Ipilimumab - 11 month(s) ago
Nivolumab plus ipilimumab showed clinically meaningful overall survival results at 3 years among special populations of patients with metastatic non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma - Full Text View - ClinicalTrials.gov - 12 month(s) ago
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I - 1 year(s) ago
AbstractBackground. An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quali
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab for an immunotherapeutic boost as a second-line treatment for mUC.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study published in @TheLancetOncol sought to examine the safety and efficacy of pairing #nivolumab induction and high-dose #ipilimumab for an immunotherapeutic boost as a second-line treatment for patients with metastatic #urothelialcarcinoma. Read more: https://t.co/5b63R7p7XY https://t.co/n57ayZMXLo
-
-
Mashup Score: 0
Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Latinx patients with mRCC demonstrated shorter PFS than non-Latinx patients after nivolumab-plus-ipilimumab treatment at a tertiary care center.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Targeted #therapies like #nivolumab & #ipilimumab focus on specific genes in #cancer cells, offering precision over traditional treatments. Dive deeper with our article & an interview with Dr. Kevin Harrington from #ASCO23. @kevhar6763 @royalmarsdenNHS https://t.co/igPBhfyv7Z